(MCRB) Seres Therapeutics, Inc. Business Model Canvas Research

Gastroenterology investigator sites are a core partner for Seres Therapeutics, Inc., because they run the ulcerative colitis and CDI studies for SER-287, SER-301, SER-262, and SER-109. These clinics handle patient recruitment, follow-up visits, and endpoint collection, which is why Seres’ SER-109 phase 3 work mattered: C. difficile recurrence was about 12% at week 8 versus 40% with placebo.

• Drives site-level patient enrollment
• Supports UC and CDI trial execution
• Captures follow-up and endpoints
• Reduces trial delay risk

For Seres, these sites are not just vendors; they are the channel that turns microbiome science into readable clinical data, especially when studies need consistent stool collection, symptom tracking, and end-of-study assessment.

Seres Therapeutics, Inc. relies on external manufacturing and analytical partners to make live bacterial consortia, since strain culture, formulation, and release testing are too specialized to run fully in-house. These partners help keep Phase and commercial lots consistent, which is critical for microbiome drugs.

• Supports strain culture and formulation
• Runs quality control and release testing
• Helps match Phase and commercial batches

Seres Therapeutics, Inc. must keep live biotherapeutics under tight chemistry, manufacturing, and controls so each lot stays true to spec. That means checking strain identity, purity, and batch consistency with quality testing that supports FDA review and patient safety.

• Lock strain identity
• Test purity every batch
• Release only consistent lots

Seres Therapeutics, Inc. runs licensing, collaboration, and tech-transfer work with partners while it keeps FDA and other regulators aligned on data packages and trial milestones. In 2025, this mattered most for SER-155 and the VOWST franchise, where partner coordination and approval steps shape timing, cost, and value capture.

• Manages partner licenses and transfers.
• Aligns data for regulatory review.
• Tracks milestones tied to approvals.

Phase III and Phase Ib data are core resources for Seres Therapeutics, Inc., because they turn the microbiome platform into proof, not just promise. SER-109 is the key validation asset: in the ECOSPOR III Phase 3 trial, 88.7% of patients were recurrence-free at week 8 versus 60.7% on placebo, and the FDA approved VOWST in 2023.

• Phase III data supports regulatory trust.
• Phase Ib data helps refine the pipeline.
• SER-109 success boosts partnering leverage.
• Strong trial data builds scientific credibility.

Seres Therapeutics, Inc. relies on a scientific team with microbiology, immunology, and clinical development skills to design live biotherapeutic products and run translational research. That know-how helped deliver Vowst, the first FDA-approved orally administered microbiota-based therapeutic, and supports discovery, trials, and partner management.

• Microbiology and immunology expertise
• Live biotherapeutic design
• Translational research and trials
• Supports one FDA-approved asset

Seres Therapeutics, Inc. uses microbiome modulation to shape host immune responses in ulcerative colitis. SER-287 and SER-301 are the key pipeline assets here, aimed at offering nontraditional inflammatory bowel disease options beyond standard anti-inflammatory drugs.

• Microbiome-driven immune control
• SER-287 and SER-301 target UC
• Nontraditional IBD treatment path

SER-401 positioned Seres Therapeutics, Inc. to extend its microbiome platform into metastatic melanoma, where checkpoint inhibitors still leave a large unmet need. In metastatic melanoma, 5-year relative survival is about 35%, so a microbiome adjunct that may lift immuno-oncology response is a clear value add.

• Targets metastatic melanoma
• Expands into cancer adjunct research
• Supports immuno-oncology response

Medical affairs support lets Seres Therapeutics, Inc. explain the science of live biotherapeutics to gastroenterologists and care centers, especially how VOWST cut recurrent C. difficile infection in ECOSPOR III to 12.4% versus 39.8% on placebo at 8 weeks. This support matters because the Company must translate mechanism, safety, and evidence into clear clinical use.

• 12.4% recurrence vs 39.8% placebo
• Phase 3 data build specialist trust
• Needed for novel live biotherapeutics

Access and reimbursement support is a core customer link for Seres Therapeutics, Inc., because specialty biotech adoption often hinges on payer coverage, prior authorization, and site-of-care approval. Specialty drugs are less than 2% of U.S. prescriptions but over half of drug spend, so help with benefits checks, appeals, and coding can speed hospital and specialty use.

• Payer approval drives uptake.
• Support reduces access delays.

Clinical trial sites are Seres Therapeutics, Inc.’s main channel for pipeline advancement: they recruit patients, handle dosing, and run follow-up across Phase Ib and Phase III studies. In 2025, this channel stayed central because late-stage trials depend on site activation speed, retention, and clean data flow.

• Drives Phase Ib and Phase III execution
• Supports recruitment, dosing, follow-up
• Main route for pipeline progress

Seres Therapeutics, Inc. uses commercial partners to widen access and share execution work, with Nestec Ltd. tied to the partnered microbiome asset VOWST. In 2025, this model mattered because Seres could lean on partner reach while its own R&D spend stayed focused on pipeline work, and congress talks plus publications kept physician awareness high.

• Partner reach expands market access
• Nestec supports microbiome commercialization
• Publications drive awareness and uptake

Metastatic melanoma patients are the target for SER-401, a microbiome immunotherapy aimed at a high-need oncology niche. Melanoma remains a specialist-treated market, with about 100,640 new U.S. cases and 8,290 deaths estimated in 2024, and metastatic disease still driving strong demand for differentiated immuno-oncology options.

• High unmet need
• Specialist oncology care
• Microbiome-based opportunity

Hospitals, physicians, and payers are the key gatekeepers for Seres Therapeutics, Inc.: hospitals and prescribers drive adoption, while payers decide reimbursement for specialty biologics. For microbially based therapies like Seres's, launch success depends on clinical evidence, prior authorization, and coverage decisions that can make or break access.

• Hospitals set formulary access.
• Physicians drive prescribing.
• Payers control reimbursement.

Seres Therapeutics, Inc. general and administrative expense reflects public-company overhead: payroll, finance, legal, SEC reporting, compliance, and board governance. In FY2025, these costs stayed in place even while programs were in development, so they remained a fixed cash burden.

• Payroll and finance support
• Legal, SEC, and audit work
• Compliance and governance costs

Licensing, collaboration management, and patent defense are material costs for Seres Therapeutics, Inc., because its value depends on protected microbiome IP and partner deals. These expenses sit inside R&D and G&A, where legal, filing, and contract work keep adding cash burn even when product sales are low.

• Negotiate and renew licenses.
• Pay for patent filing and defense.
• Run partner oversight and legal work.
• Cover contract and admin costs.

Royalties on partnered products give Seres Therapeutics, Inc. a long-tail revenue stream once a partner commercializes the asset, so cash can keep coming after the heavy development spend is done. This matters most when commercialization rights sit with the partner, because Seres can earn without running the sales force or inventory.

• Partner-led launch, lower execution risk
• Revenue tied to net sales
• Strongest after clinical success
• Long-tail cash with limited extra spend

Program transfer and asset proceeds can bring Seres Therapeutics, Inc. one-time cash, such as the $175 million upfront from the VOWST sale to Nestlé Health Science. That kind of rights transfer can fund the rest of the pipeline without new equity.

• One-time cash, not recurring revenue
• Fits out-license or sale deals
• Supports pipeline funding